利拉利汀钠盐
利拉利汀钠盐 性质
熔点 | 120-122°C |
---|---|
储存条件 | Amber Vial, -20°C Freezer, Under Inert Atmosphere |
溶解度 | 可溶于DMSO(少许)、甲醇(少许) |
形态 | 固体 |
颜色 | 淡黄色至黄色凝胶至 |
稳定性 | 感光 |
利拉利汀钠盐 用途与合成方法
Disposition of Seco Rapamycin in Human Tissue Homogenates and Caco-2 Cell Monolayers. To determine whether Seco Rapamycin (D2) can be metabolized to dihydro Sirolimus (M2), 20 μM Seco Rapamycin is incubated with human liver, jejunal mucosal, and Caco-2 homogenates. All of these homogenates produced M2 in an NADPH-dependent manner. Ketoconazole, at a high concentration (100 μM), has no effect on the formation of M2 in any of the homogenates examined. To determine whether Seco Rapamycin can be metabolized to M2 in intact cells, 20 μM Seco Rapamycin is added to Caco-2 cell monolayers. When applied to the apical compartment, little Seco Rapamycin is detected in the basolateral compartment and in the cellular fraction after 4 h. In addition, little M2 is detected. LY335979 has little effect on the distribution of Seco Rapamycin after an apical dose, although M2 became detectable in the apical compartment. In contrast, when Seco Rapamycin is applied to the basolateral compartment, both Seco Rapamycin and M2 are readily detected in the apical compartment; LY335679 decreases the flux of Seco Rapamycin to the apical compartment and increases the amount of M2 in both apical and basolateral compartments.
利拉利汀钠盐 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-19555A | 1 mg | 1590 | ||
2024-11-08 | HY-19555A | 利拉利汀钠盐 | 148554-65-8 | 5mg | 3500 |